GO:1902369 negative regulation of RNA catabolic process: RNA Stability Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902369 (negative regulation of RNA catabolic process) describes any process that stops, prevents or reduces the frequency, rate or extent of RNA catabolic process.
• It is a biological_process term that sits at the intersection of RNA modification, RNA-binding protein function and transcript stability control [1,2,5].
• m6A and m5C RNA modifications can stabilize specific transcripts and thereby suppress their catabolism, as shown for METTL14, METTL3 and NSUN4 [1,3,4].
• RNA-binding proteins such as SP140, CELF1, Jab1 and MEX3C directly modulate mRNA stability and downstream signaling [2,6,7,8].
• Dysregulation of this process contributes to leukemia, neuroinflammation, glioma, metabolic beiging defects and cancer drug sensitivity [1,3,4,6,7].
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test causality of candidate stabilizers in this pathway [1,2,3,4,6,7,8].
Description
GO:1902369, negative regulation of RNA catabolic process, is a Gene Ontology biological_process term defined as any process that stops, prevents or reduces the frequency, rate or extent of RNA catabolic process. In practical terms, it covers the cellular strategies that protect RNA molecules from degradation, thereby extending their half-life and allowing sustained protein output [2,5]. This regulation is critical because RNA catabolic processes are tightly controlled to balance transcript availability with cellular demand. Recent transcriptome-wide studies using nanopore direct RNA sequencing have revealed extensive crosstalk between RNA modifications and regulatory features that influence transcript stability. Understanding GO:1902369 therefore requires integrating RNA modification enzymes, RNA-binding proteins and the decay machinery they oppose [1,2,5]. The importance of negative regulation of RNA catabolic process spans development, immunity and disease. For example, METTL14-dependent m6A modification stabilizes specific mRNAs and inhibits hematopoietic stem/progenitor differentiation while promoting leukemogenesis. Similarly, METTL3 stabilizes BATF mRNA in microglia, driving neuroinflammation and neurotoxicity. NSUN4-mediated 5-methylcytosine modification improves CDC42 mRNA stabilization and promotes malignant progression of glioma. These examples illustrate that suppressing RNA catabolism is not a passive event but an actively regulated program with profound phenotypic consequences [1,3,4]. Researchers study GO:1902369 to identify the cis-elements, trans-acting factors and modifications that determine transcript lifetime [2,5,6,7,8]. The pathway is also a therapeutic target: modulating mRNA stability can sensitize tumors to PARP inhibitors or alter metabolic phenotypes such as white fat beiging [6,7]. This article summarizes the definition, mechanisms, key genes, disease links and experimental methods for investigating negative regulation of RNA catabolic process, with emphasis on CRISPR-based models that establish causality [1,2,3,4,6,7,8].
negative regulation of RNA catabolic process At A Glance
| GO ID | GO:1902369 |
|---|---|
| GO term | negative regulation of RNA catabolic process |
| Ontology | biological_process |
| Synonym | negative regulation of RNA degradation; negative regulation of RNA catabolism; inhibition of RNA breakdown; downregulation of RNA catabolic process |
| Major function | Stops, prevents or reduces the frequency, rate or extent of RNA catabolic process, thereby stabilizing RNA transcripts |
| Biological context | RNA modification, RNA-binding protein activity, transcript stability control, cellular stress and immune responses |
| Representative modifiers | METTL14, METTL3, NSUN4, SP140, CELF1, Jab1, MEX3C |
| Disease relevance | Leukemia, neuroinflammation, glioma, cancer drug sensitivity, metabolic disorders |
| Research methods | Nanopore direct RNA sequencing, RNA-seq, Ribo-seq, CRISPR KO/point mutation/knock-in/overexpression, RNA immunoprecipitation |
What Is GO:1902369?
In our own words, GO:1902369 (negative regulation of RNA catabolic process) refers to any cellular process that reduces, prevents or stops the breakdown of RNA molecules. It includes mechanisms that protect transcripts from exonucleases or endonucleases, stabilize RNA secondary structure, recruit stabilizing RNA-binding proteins, or remove marks that would otherwise target RNA for decay. The term is a biological_process and is not restricted to a single RNA class or decay pathway; it encompasses regulation of mRNA, non-coding RNA and other RNA catabolic processes. Its synonyms include negative regulation of RNA degradation, negative regulation of RNA catabolism and inhibition of RNA breakdown, reflecting the same concept of extending RNA lifetime.
Why Is negative regulation of RNA catabolic process Important in Cell Biology?
Negative regulation of RNA catabolic process is important because it determines how long an RNA molecule persists and how much protein can be produced from it. By suppressing RNA decay, cells can rapidly amplify specific gene expression programs without new transcription, which is essential for responses to stress, immune challenge and developmental cues [2,5]. Disruption of this regulation leads to inappropriate stabilization of oncogenic or inflammatory transcripts, contributing to diseases such as leukemia, glioma and neuroinflammation [1,3,4]. Conversely, understanding how to enhance RNA catabolism could be used to eliminate pathogenic transcripts. Therefore, GO:1902369 is a central node for both basic RNA biology and therapeutic development [1,2,3,4,6,7,8].
• Controls transcript half-life and protein output without requiring new transcription.
• Integrates RNA modifications such as m6A and m5C with decay machinery [1,3,4].
• Enables rapid immune and stress responses by stabilizing interferon and inflammatory mRNAs [2,3].
• Promotes leukemogenesis by stabilizing oncogenic transcripts in hematopoietic stem/progenitor cells.
• Drives malignant progression in glioma through CDC42 mRNA stabilization.
• Modulates metabolic phenotypes such as white fat beiging via Dio2 mRNA stabilization.
• Influences PARP inhibitor sensitivity in triple-negative breast cancer through HRR mRNA stability.
• Contributes to hepatocellular carcinoma metastasis via SOCS3 mRNA decay regulation.
• Provides therapeutic targets for modulating RNA stability in cancer and inflammation [1,2,3,4,6,7,8].
• Requires CRISPR-based causal models to distinguish correlation from causation in RNA stability studies [1,2,3,4,6,7,8].
What Happens During negative regulation of RNA catabolic process?
Recognition of RNA substrates and stabilizing marks
In simple terms: The cell first identifies which RNAs should be protected from degradation.
Negative regulation of RNA catabolic process begins with the recognition of specific RNA features that recruit stabilizing factors. RNA modifications such as m6A and m5C can serve as marks that influence transcript fate [1,3,4]. Nanopore direct RNA sequencing has revealed complex crosstalk between mRNA modifications and regulatory features, showing that modification patterns are linked to transcript stability. For example, METTL14-mediated m6A modification inhibits hematopoietic stem/progenitor differentiation by stabilizing specific mRNAs, while NSUN4-mediated m5C promotes CDC42 mRNA stabilization in glioma. These recognition events determine whether an RNA will be targeted for decay or protected.
Recruitment of stabilizing RNA-binding proteins
In simple terms: Protective proteins bind to the RNA and shield it from degradation.
Once a transcript is marked for protection, RNA-binding proteins are recruited to prevent catabolism. SP140 regulates interferon mRNA stability and antiviral immunity, acting as a stabilizing factor. CELF1 promotes beiging of white fat by stabilizing Dio2 mRNA. Jab1 regulates homologous recombination repair (HRR) mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. These examples demonstrate that specific RNA-binding proteins can directly oppose RNA catabolic processes and sustain transcript levels [2,6,7].
Suppression of decay machinery and exonuclease activity
In simple terms: The normal degradation enzymes are blocked or diverted away from the protected RNA.
Negative regulation of RNA catabolic process ultimately requires inhibition or evasion of the decay machinery. MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling in hepatocellular carcinoma, illustrating that when decay is not suppressed, signaling is altered. Conversely, stabilization of BATF mRNA by METTL3 in microglia drives neuroinflammation, showing that blocking decay can have pathological consequences. The balance between decay and stabilization is therefore a key determinant of cellular outcomes [3,8].
Functional consequences for gene expression
In simple terms: The protected RNA lasts longer and produces more protein, changing cell behavior.
The functional outcome of negative regulation of RNA catabolic process is increased transcript abundance and prolonged protein synthesis. This can alter differentiation, immune responses and metabolic programs [1,2,6]. For instance, METTL14-mediated stabilization inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis. SP140-dependent interferon mRNA stabilization supports antiviral immunity. CELF1-mediated Dio2 mRNA stabilization promotes white fat beiging. Thus, this process directly shapes cell fate and physiology [1,2,6].
Key Genes Involved in GO:1902369 negative regulation of RNA catabolic process
The following genes and proteins are experimentally implicated in negative regulation of RNA catabolic process, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL14 | m6A methyltransferase that stabilizes specific mRNAs | Inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis |
| METTL3 | m6A methyltransferase that stabilizes BATF mRNA | Drives neuroinflammation and neurotoxicity in microglia |
| NSUN4 | m5C methyltransferase that promotes CDC42 mRNA stabilization | Promotes malignant progression of glioma |
| SP140 | RNA-binding protein regulating interferon mRNA stability | Controls antiviral immunity |
| CELF1 | Adipocyte RNA-binding protein stabilizing Dio2 mRNA | Promotes beiging of white fat |
| Jab1 | Regulator of HRR mRNA stability | Modulates PARP inhibitor sensitivity in triple-negative breast cancer |
| MEX3C | Mediates decay of SOCS3 mRNA | Promotes JAK2/STAT3 signaling and metastasis in hepatocellular carcinoma |
| BATF | Transcription factor whose mRNA is stabilized by METTL3 | Neuroinflammation and neurotoxicity |
| CDC42 | Small GTPase whose mRNA is stabilized by NSUN4 | Glioma malignant progression |
| Dio2 | Thyroid hormone activating enzyme whose mRNA is stabilized by CELF1 | White fat beiging |
| SOCS3 | Suppressor of cytokine signaling whose mRNA is degraded by MEX3C | Hepatocellular carcinoma metastasis |
| HRR genes | Homologous recombination repair transcripts stabilized by Jab1 | PARP inhibitor sensitivity in breast cancer |
| Interferon mRNAs | Cytokine transcripts stabilized by SP140 | Antiviral immunity |
| m6A-modified mRNAs | Transcripts bearing m6A marks that affect stability | Hematopoietic differentiation and leukemogenesis |
| m5C-modified mRNAs | Transcripts bearing m5C marks that affect stability | Glioma progression |
| Nanopore-detected modified RNAs | Transcripts with complex modification crosstalk | Global analysis of mRNA modifications and stability |
How Is negative regulation of RNA catabolic process Regulated?
Negative regulation of RNA catabolic process is itself regulated at multiple levels. RNA modification enzymes such as METTL14, METTL3 and NSUN4 deposit marks that can recruit stabilizing factors or block decay [1,3,4]. RNA-binding proteins like SP140, CELF1, Jab1 and MEX3C compete with or modulate the decay machinery [2,6,7,8]. Global transcriptome studies using nanopore direct RNA sequencing have shown that mRNA modifications and regulatory features exhibit extensive crosstalk, suggesting that stability is controlled by combinatorial signals rather than a single switch. The balance between stabilizing and destabilizing factors determines the net rate of RNA catabolism for each transcript [2,5,8].
negative regulation of RNA catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL14 | Leukemia, hematopoietic stem/progenitor differentiation | Knockout and point-mutation models in hematopoietic cell lines |
| METTL3 | Neuroinflammation, neurotoxicity | Microglial knockout and overexpression models |
| NSUN4 | Glioma malignant progression | Glioma cell lines with knockout or knock-in of NSUN4 |
| Jab1 | Triple-negative breast cancer, PARP inhibitor sensitivity | Breast cancer cell lines with Jab1 knockout or overexpression |
| MEX3C | Hepatocellular carcinoma metastasis | Liver cancer cell lines with MEX3C knockout or knockdown |
Leukemia and hematopoietic differentiation
METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification, demonstrating that negative regulation of RNA catabolic process can drive hematological malignancy. Stabilization of specific mRNAs by METTL14 alters the differentiation program of hematopoietic stem and progenitor cells, contributing to leukemia development.
Neuroinflammation and neurotoxicity
METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia. This illustrates how suppression of RNA catabolism in immune cells of the brain can sustain inflammatory gene expression and contribute to neuronal damage.
Glioma progression
NSUN4-mediated RNA 5-methylcytosine promotes malignant progression of glioma through improving CDC42 mRNA stabilization. Stabilization of CDC42 mRNA enhances its protein output, supporting invasive and proliferative phenotypes in glioma cells.
Cancer therapy sensitivity and metastasis
Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. In hepatocellular carcinoma, MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling and facilitates metastasis. These examples show that both stabilization and destabilization of specific transcripts can influence cancer progression and treatment response [7,8].
From negative regulation of RNA catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of METTL14 affect RNA stability and differentiation? | METTL14 knockout in hematopoietic stem/progenitor cells |
| Does METTL3-mediated BATF mRNA stabilization drive neuroinflammation? | METTL3 knockout or point-mutation in microglia |
| Does NSUN4-mediated m5C stabilize CDC42 mRNA in glioma? | NSUN4 knockout or knock-in in glioma cells |
| Does SP140 stabilize interferon mRNA? | SP140 knockout or tagged knock-in in immune cells |
| Does CELF1 stabilize Dio2 mRNA during beiging? | CELF1 knockout or overexpression in adipocytes |
| Does Jab1 regulate HRR mRNA stability and PARP inhibitor response? | Jab1 knockout or overexpression in breast cancer cells |
How to Study the negative regulation of RNA catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nanopore direct RNA sequencing | RNA modifications and full-length transcript features | Global analysis of modification crosstalk and stability |
| RNA-seq | Transcript abundance | Measuring changes in mRNA levels after gene perturbation [1,3,4] |
| Ribo-seq | Translation efficiency | Linking mRNA stabilization to protein output [1,3,4] |
| RNA immunoprecipitation (RIP) | RNA-protein binding | Identifying targets of SP140, CELF1, Jab1, MEX3C [2,6,7,8] |
| CLIP | Direct RNA-protein interaction sites | Mapping binding sites of stabilizing proteins [2,6,7,8] |
| CRISPR knockout | Loss-of-function phenotype | Testing necessity of candidate genes [1,2,3,4,6,7,8] |
| CRISPR knock-in | Tagged or mutant protein expression | Tracking localization and function of stabilizers [1,2,3,4,6,7,8] |
| Overexpression | Gain-of-function phenotype | Testing sufficiency of candidate genes [1,2,3,4,6,7,8] |
Nanopore direct RNA sequencing for modification and stability analysis
Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features. This method allows researchers to detect RNA modifications and link them to transcript stability, providing a global view of negative regulation of RNA catabolic process.
RNA-seq and Ribo-seq for transcript abundance and translation
RNA-seq measures transcript levels, while Ribo-seq measures translation efficiency. Together they can reveal whether stabilization of an mRNA leads to increased protein output, as seen for METTL14, METTL3 and NSUN4 targets [1,3,4].
RNA immunoprecipitation and CLIP for RNA-protein interactions
RNA immunoprecipitation and CLIP-based methods identify direct binding between RNA-binding proteins and their target transcripts. These approaches have been used to study SP140, CELF1, Jab1 and MEX3C interactions with mRNAs [2,6,7,8].
CRISPR-based functional assays for causality
CRISPR knockout, point-mutation, knock-in and overexpression models are essential to establish causal roles of candidate genes in negative regulation of RNA catabolic process [1,2,3,4,6,7,8]. These models allow researchers to test whether a specific gene is necessary or sufficient for transcript stabilization and downstream phenotypes.
How CRISPR Can Be Used to Study GO:1902369 negative regulation of RNA catabolic process
Knockout
CRISPR knockout is used to delete genes such as METTL14, METTL3, NSUN4, SP140, CELF1, Jab1 or MEX3C to test whether they are required for negative regulation of RNA catabolic process [1,2,3,4,6,7,8]. Loss-of-function models reveal changes in target mRNA stability and downstream phenotypes, such as differentiation block or altered drug sensitivity [1,7].
Point Mutation
Point mutations can be introduced into catalytic residues or modification sites to dissect specific functions. For example, mutating the methyltransferase domain of METTL14 or METTL3 can separate m6A deposition from other activities [1,3]. Similarly, point mutations in NSUN4 can test the importance of m5C modification for CDC42 mRNA stabilization.
Knock-in
Knock-in of tagged or reporter versions of genes such as SP140, CELF1 or Jab1 allows tracking of protein localization and interaction with RNA targets [2,6,7]. Knock-in of disease-associated mutations can also model how specific variants affect RNA stability regulation [1,2,3,4,6,7,8].
Overexpression
Overexpression of candidate stabilizers such as METTL14, METTL3, NSUN4, SP140, CELF1 or Jab1 tests whether increased levels are sufficient to enhance RNA stability and drive phenotypes like leukemogenesis, neuroinflammation or beiging [1,2,3,4,6,7]. Overexpression models are also useful for testing therapeutic hypotheses [1,2,3,4,6,7,8].
How EDITGENE Supports negative regulation of RNA catabolic process Research
Researchers studying negative regulation of RNA catabolic process-related genes often need to determine whether a candidate gene is causally involved in transcript stabilization or whether its correlation with RNA levels is secondary to other cellular changes. Establishing causality requires precise genetic models that can delete, mutate, tag or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR-based services to support such studies, from knockout and point-mutation models to knock-in reporters and overexpression lines, as well as library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of RNA catabolic process research.
Frequently Asked Questions About negative regulation of RNA catabolic process
What is GO:1902369 negative regulation of RNA catabolic process?
GO:1902369 is a Gene Ontology biological_process term defined as any process that stops, prevents or reduces the frequency, rate or extent of RNA catabolic process.
What genes are involved in negative regulation of RNA catabolic process?
Genes experimentally implicated include METTL14, METTL3, NSUN4, SP140, CELF1, Jab1 and MEX3C, among others [1,2,3,4,6,7,8].
How does METTL14 regulate RNA stability?
METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification, which stabilizes specific transcripts.
How does METTL3 affect neuroinflammation?
METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.
What is the role of NSUN4 in glioma?
NSUN4-mediated RNA 5-methylcytosine promotes malignant progression of glioma through improving CDC42 mRNA stabilization.
How does SP140 regulate antiviral immunity?
SP140 regulates interferon mRNA stability and antiviral immunity, acting as a stabilizing factor.
What is the link between CELF1 and white fat beiging?
Adipocyte RNA-binding protein CELF1 promotes beiging of white fat through stabilizing Dio2 mRNA.
How does Jab1 affect PARP inhibitor sensitivity?
Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.
What methods are used to study negative regulation of RNA catabolic process?
Methods include nanopore direct RNA sequencing, RNA-seq, Ribo-seq, RNA immunoprecipitation, CLIP and CRISPR-based functional assays [1,2,3,4,5,6,7,8].
Why is negative regulation of RNA catabolic process important in cancer?
It can stabilize oncogenic or repair transcripts, contributing to leukemia, glioma, breast cancer drug sensitivity and hepatocellular carcinoma metastasis [1,4,7,8].
Conclusion
GO:1902369 negative regulation of RNA catabolic process is a fundamental biological process that controls transcript lifetime and protein output. Through RNA modifications and RNA-binding proteins such as METTL14, METTL3, NSUN4, SP140, CELF1, Jab1 and MEX3C, cells can protect specific mRNAs from degradation and drive phenotypes ranging from leukemogenesis to neuroinflammation and metabolic remodeling [1,2,3,4,6,7,8]. Understanding this process requires integrating global RNA modification analysis with precise CRISPR-based causal models [1,2,3,4,5,6,7,8]. As research advances, targeting negative regulation of RNA catabolic process may offer therapeutic opportunities in cancer, inflammation and metabolic disease [1,2,3,4,6,7,8]. EDITGENE provides the CRISPR tools and bioinformatics support needed to accelerate these discoveries.
References
- 1. Weng H et al.. 2018. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification.. Cell Stem Cell 22(2):191-205.e9 PMID: 29290617
- 2. Witt KC et al.. 2025. SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity.. Nature 643(8074):1372-1380 PMID: 40500448
- 3. Wu X et al.. 2025. The m(6)A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.. Cell Death Differ 32(1):100-117 PMID: 38902548
- 4. Zhao Z et al.. 2024. NSUN4 mediated RNA 5-methylcytosine promotes the malignant progression of glioma through improving the CDC42 mRNA stabilization.. Cancer Lett 597:217059 PMID: 38876383
- 5. Kim Y et al.. 2025. Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features.. Cell Genom 5(6):100872 PMID: 40359935
- 6. Zeng T et al.. 2025. Adipocyte RNA-binding protein CELF1 promotes beiging of white fat through stabilizing Dio2 mRNA.. Nat Commun 16(1):7414 PMID: 40789858
- 7. Peng X et al.. 2025. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.. Mol Cancer 24(1):217 PMID: 40819058
- 8. Xiao Y et al.. 2022. MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.. Cancer Res 82(22):4191-4205 PMID: 36112698
